Replies to post #1794 on Entremed (ENMD)

[reason4]

EntreMed to Participate in Anti-Angiogenesis Panel at BIO CEO Conference
2/18/2005 8:07:00 AM  - PR Newswire



ROCKVILLE, Md., Feb 18, 2005 /PRNewswire-FirstCall via COMTEX/ --

EntreMed, Inc.(Nasdaq: ENMD), a clinical-stage pharmaceutical company developingtherapeutics primarily for the treatment of cancer and inflammatory diseases,today announced James S. Burns, President & CEO, will participate in a paneldiscussion on "Starving Cancer" at the 2005 Biotechnology IndustryOrganization (BIO) CEO & Investor Conference being held February 23-24, 2005in New York. The panel will be held February 24th from 9:30 a.m. to 10:55 a.m.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns will join biotechnology industry leaders to discuss the latestapproaches and clinical progress of both anti-angiogenesis and vasculartargeting agents. Starving tumors and the blood vessels that nourish them hasbeen the focus of breakthrough discoveries by many companies and leadingcancer researchers. EntreMed's lead compound, Panzem(R) NCD(2-methoxyestradiol or 2ME2) and its second generation 2ME2 analog, ENMD-1198,both work through multiple mechanisms that attack tumor cells directly, aswell as the blood vessels that nourish them.The panel discussion will include an overview of the current state ofangiogenesis, an overview from participating companies, and a question andanswer session immediately following the formal presentations. The focussession will be web cast and will be available on the Company's web site athttp://www.entremed.com and the conference web site at http://www.ceo.bio.orgapproximately 24 hours after the event.